Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 15 Best Passive Income Stocks to Buy Right Now.
On November 12, Scotiabank analyst Louise Chen began coverage on ten large-cap biopharma companies and shared an “out-of-consensus” positive view on the sector, according to a report by The Fly. She pointed out that years of underperformance in large cap biopharma stocks, compared with other sectors and the major indices, could offer an attractive entry point before the next wave of innovation, where companies “will be treating to cure.” The firm kept its Outperform rating on Gilead Sciences, Inc..
Gilead Sciences, Inc. remains a dependable dividend payer. Its shares have climbed more than 36% since the beginning of 2025, beating the broader market. The biotech continues to lead the HIV drug market, which still drives most of its growth. In the third quarter, total revenue rose 3% from a year earlier to reach $7.8 billion.
Gilead Sciences, Inc. has pushed forward in oncology in recent years, although progress has not been without challenges. Oncology revenue fell 3% year over year to $788 million in the third quarter. Even so, the company has a large and active oncology pipeline, one that is now bigger than its HIV portfolio. Over the coming years, the company is expected to benefit from label expansions and new approvals in the cancer market, which should help move overall sales higher.
READ NEXT: 15 Extreme Dividend Stocks to Buy According to Hedge Funds and 15 Overlooked Dividend Stocks to Buy Right Now.
